Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors

Amber E. Bannon, Lillian R. Klug, Christopher Corless, Michael Heinrich

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: The diagnosis and treatment of gastrointestinal stromal tumor (GIST) has emerged as a paradigm for modern cancer treatment (‘precision medicine’), as it highlights the importance of matching molecular defects with specific therapies. Over the past two decades, the molecular classification and diagnostic work up of GIST has been radically transformed, accompanied by the development of molecular therapies for specific subgroups of GIST. This review summarizes the developments in the field of molecular diagnosis of GIST, particularly as they relate to optimizing medical therapy. Areas covered: Based on an extensive literature search of the molecular and clinical aspects of GIST, the authors review the most important developments in this field with an emphasis on the differential diagnosis of GIST including mutation testing, therapeutic implications of each molecular subtype, and emerging technologies relevant to the field. Expert commentary: The use of molecular diagnostics to classify GIST has been shown to be successful in optimizing patient treatment, but these methods remain under-utilized. In order to facilitate efficient and comprehensive molecular testing, the authors have developed a decision tree to aid clinicians.

Original languageEnglish (US)
Pages (from-to)445-457
Number of pages13
JournalExpert Review of Molecular Diagnostics
Volume17
Issue number5
DOIs
StatePublished - May 4 2017

Fingerprint

Molecular Diagnostic Techniques
Gastrointestinal Stromal Tumors
Molecular Pathology
Therapeutics
Decision Trees
Precision Medicine
Differential Diagnosis
Technology
Mutation

Keywords

  • BRAF
  • Gastrointestinal stromal tumors
  • imatinib
  • KIT
  • KRAS
  • NF1
  • PDGFRA
  • receptor tyrosine kinases
  • regorafenib
  • RTK translocations
  • SDH
  • sunitinib

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. / Bannon, Amber E.; Klug, Lillian R.; Corless, Christopher; Heinrich, Michael.

In: Expert Review of Molecular Diagnostics, Vol. 17, No. 5, 04.05.2017, p. 445-457.

Research output: Contribution to journalReview article

@article{a3eb7fba5aa84387a06f9e977e703e15,
title = "Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors",
abstract = "Introduction: The diagnosis and treatment of gastrointestinal stromal tumor (GIST) has emerged as a paradigm for modern cancer treatment (‘precision medicine’), as it highlights the importance of matching molecular defects with specific therapies. Over the past two decades, the molecular classification and diagnostic work up of GIST has been radically transformed, accompanied by the development of molecular therapies for specific subgroups of GIST. This review summarizes the developments in the field of molecular diagnosis of GIST, particularly as they relate to optimizing medical therapy. Areas covered: Based on an extensive literature search of the molecular and clinical aspects of GIST, the authors review the most important developments in this field with an emphasis on the differential diagnosis of GIST including mutation testing, therapeutic implications of each molecular subtype, and emerging technologies relevant to the field. Expert commentary: The use of molecular diagnostics to classify GIST has been shown to be successful in optimizing patient treatment, but these methods remain under-utilized. In order to facilitate efficient and comprehensive molecular testing, the authors have developed a decision tree to aid clinicians.",
keywords = "BRAF, Gastrointestinal stromal tumors, imatinib, KIT, KRAS, NF1, PDGFRA, receptor tyrosine kinases, regorafenib, RTK translocations, SDH, sunitinib",
author = "Bannon, {Amber E.} and Klug, {Lillian R.} and Christopher Corless and Michael Heinrich",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14737159.2017.1308826",
language = "English (US)",
volume = "17",
pages = "445--457",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors

AU - Bannon, Amber E.

AU - Klug, Lillian R.

AU - Corless, Christopher

AU - Heinrich, Michael

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: The diagnosis and treatment of gastrointestinal stromal tumor (GIST) has emerged as a paradigm for modern cancer treatment (‘precision medicine’), as it highlights the importance of matching molecular defects with specific therapies. Over the past two decades, the molecular classification and diagnostic work up of GIST has been radically transformed, accompanied by the development of molecular therapies for specific subgroups of GIST. This review summarizes the developments in the field of molecular diagnosis of GIST, particularly as they relate to optimizing medical therapy. Areas covered: Based on an extensive literature search of the molecular and clinical aspects of GIST, the authors review the most important developments in this field with an emphasis on the differential diagnosis of GIST including mutation testing, therapeutic implications of each molecular subtype, and emerging technologies relevant to the field. Expert commentary: The use of molecular diagnostics to classify GIST has been shown to be successful in optimizing patient treatment, but these methods remain under-utilized. In order to facilitate efficient and comprehensive molecular testing, the authors have developed a decision tree to aid clinicians.

AB - Introduction: The diagnosis and treatment of gastrointestinal stromal tumor (GIST) has emerged as a paradigm for modern cancer treatment (‘precision medicine’), as it highlights the importance of matching molecular defects with specific therapies. Over the past two decades, the molecular classification and diagnostic work up of GIST has been radically transformed, accompanied by the development of molecular therapies for specific subgroups of GIST. This review summarizes the developments in the field of molecular diagnosis of GIST, particularly as they relate to optimizing medical therapy. Areas covered: Based on an extensive literature search of the molecular and clinical aspects of GIST, the authors review the most important developments in this field with an emphasis on the differential diagnosis of GIST including mutation testing, therapeutic implications of each molecular subtype, and emerging technologies relevant to the field. Expert commentary: The use of molecular diagnostics to classify GIST has been shown to be successful in optimizing patient treatment, but these methods remain under-utilized. In order to facilitate efficient and comprehensive molecular testing, the authors have developed a decision tree to aid clinicians.

KW - BRAF

KW - Gastrointestinal stromal tumors

KW - imatinib

KW - KIT

KW - KRAS

KW - NF1

KW - PDGFRA

KW - receptor tyrosine kinases

KW - regorafenib

KW - RTK translocations

KW - SDH

KW - sunitinib

UR - http://www.scopus.com/inward/record.url?scp=85018652339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018652339&partnerID=8YFLogxK

U2 - 10.1080/14737159.2017.1308826

DO - 10.1080/14737159.2017.1308826

M3 - Review article

C2 - 28317407

AN - SCOPUS:85018652339

VL - 17

SP - 445

EP - 457

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 5

ER -